13569-96-5

Usage

Uses

Used in Organic Synthesis:
4-(4-BROMO-PHENYL)-1H-IMIDAZOLE is used as a building block in organic synthesis for the creation of various biologically active compounds and materials. Its unique structure and properties make it a valuable component in the synthesis process.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-(4-BROMO-PHENYL)-1H-IMIDAZOLE is used as a key intermediate in the development of pharmaceutical drugs and fine chemicals. Its potential applications in this field are vast, as it can contribute to the creation of new and innovative medications.
Used in Medicinal Chemistry:
4-(4-BROMO-PHENYL)-1H-IMIDAZOLE is used as a compound with potential pharmacological activities and therapeutic potential in the field of medicinal chemistry. Its unique structure and properties make it a promising candidate for further research and development in this area.

InChI:InChI=1/C9H7BrN2/c10-8-3-1-7(2-4-8)9-5-11-6-12-9/h1-6H,(H,11,12)

Upstream product

• 50-00-0 formaldehyd 
• 3343-45-1 4-bromo-2-hydroxyacetophenone 
• 77287-34-4 formamide 
• 99-73-0 para-bromophenacyl bromide 
• 1021919-40-3 2-(4-bromophenyl)-4-tosyloxazole 
• 1122-91-4 4-bromo-benzaldehyde 
• 67-56-1 methanol 

Downstream Products

• 773893-61-1 2-[4-(4-bromophenyl)-1H-imidazol-1-yl]pyridine 
• 1021919-41-4 5-(4-(trimethylstannyl)phenyl)-1H-imidazole 
• 670-91-7 4-(p-tolyl)-1H-imidazole 
• 1609658-41-4 1-(4-benzyloxybenzyl)-4-(4-bromophenyl)-1H-imidazole 
• 136350-70-4 4-(4-bromophenyl)-1-methyl-1H-imidazole 

Relevant academic research and scientific papers

Preparation of Imidazole Derivatives via Bisfunctionalization of Alkynes Catalyzed by Ruthenium Carbonyl

A one-step, oxidative bisfunctionalization of alkynes to generate cis -enediol diacetates catalyzed by ruthenium carbonyl (triruthenium dodecacarbonyl) is presented. The reaction was performed using the alkyne, (diacetoxyiodo)benzene, Ru 3 (CO) 12 as the catalyst, and toluene as the solvent at 100 °C to give the cis -enediol diacetates in up to 82percent yields. This method overcomes the shortcomings of existing methods, such as tedious reaction steps, substrate limitations, and the use of toxic reagents. Furthermore, the reaction of module cis -enediol diacetates with ammonium carbonate [(NH 4) 2 CO 3 ] in an alcohol solvent gave imidazole derivatives in 37-84percent yields, thus providing a simple and mild new method for the synthesis of imidazole compounds.

SPIROCYCLIC COMPOUNDS

Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

IDO inhibitors

Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R1, R4, and R5 are defined herein. Such compounds and compositions are useful for mod

Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2- ones as potent and selective mTOR kinase inhibitors

We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3Kα lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).

IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS

The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

4-RING IMIDAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

Imidazole compounds of Formula (I): (where A, B, R11, R12, W, X. Y and Z are as defined herein) wherein the imidazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl a